Previous Article | Next Article 
Journal of Virology, January 2000, p. 702-709, Vol. 74, No. 2
0022-538X/00/$04.00+0
Copyright © 2000, American Society for Microbiology. All rights reserved.
Functional Characterization of Intracellular and
Secreted Forms of a Truncated Hepatitis C Virus E2
Glycoprotein
Mike
Flint,1
Jean
Dubuisson,2
Catherine
Maidens,1
Richard
Harrop,3
Geoffrey R.
Guile,3
Persephone
Borrow,3 and
Jane A.
McKeating1,*
School of Animal and Microbial Sciences,
University of Reading, Whiteknights, Reading RG6
6AJ,1 and The Edward Jenner Institute
for Vaccine Research, Compton, Newbury RG20
7NN,3 United Kingdom, and Equipe
Hepatite C, CNRS-UMR 8526, Institut de Biologie de Lille et Institut
Pasteur de Lille, 59021 Lille Cedex, France2
Received 6 July 1999/Accepted 19 October 1999
The E2 protein of hepatitis C virus (HCV) is believed to be a
virion surface glycoprotein that is a candidate for inclusion in an
antiviral vaccine. A truncated soluble version of E2 has recently been
shown to interact with CD81, suggesting that this protein may be a
component of the receptor for HCV. When expressed in eukaryotic cells,
a significant proportion of E2 forms misfolded aggregates. To analyze
the specificity of interaction between E2 and CD81, the aggregated and
monomeric forms of a truncated E2 glycoprotein (E2661) were
separated by high-pressure liquid chromatography and analyzed for CD81
binding. Nonaggregated forms of E2 preferentially bound CD81 and a
number of conformation-dependent monoclonal antibodies (MAbs).
Furthermore, intracellular forms of E2661 were found to
bind CD81 with greater affinity than the extracellular forms.
Intracellular and secreted forms of E2661 were also found
to differ in reactivity with MAbs and human sera, consistent with
differences in antigenicity. Together, these data indicate that proper
folding of E2 is important for its interaction with CD81 and that
modifications of glycans can modulate this interaction. Identification
of the biologically active forms of E2 will assist in the future design
of vaccines to protect against HCV infection.
*
Corresponding author. Present address: Pfizer Ltd.,
Central Research, Sandwich, Kent CT13 9NJ, United Kingdom. Phone: (44) 1304 616 161. Fax: (44) 1304 658 480. E-mail:
jane_mckeating{at}sandwich.pfizer.com.

Publication no. 10 from the Edward Jenner Institute for Vaccine
Research.
Journal of Virology, January 2000, p. 702-709, Vol. 74, No. 2
0022-538X/00/$04.00+0
Copyright © 2000, American Society for Microbiology. All rights reserved.
This article has been cited by other articles:
-
Timpe, J M, McKeating, J A
(2008). Hepatitis C virus entry: possible targets for therapy. Gut
57: 1728-1737
[Full Text]
-
Chapel, C., Garcia, C., Bartosch, B., Roingeard, P., Zitzmann, N., Cosset, F.-L., Dubuisson, J., Dwek, R. A., Trepo, C., Zoulim, F., Durantel, D.
(2007). Reduction of the infectivity of hepatitis C virus pseudoparticles by incorporation of misfolded glycoproteins induced by glucosidase inhibitors. J. Gen. Virol.
88: 1133-1143
[Abstract]
[Full Text]
-
Owsianka, A. M., Timms, J. M., Tarr, A. W., Brown, R. J. P., Hickling, T. P., Szwejk, A., Bienkowska-Szewczyk, K., Thomson, B. J., Patel, A. H., Ball, J. K.
(2006). Identification of conserved residues in the e2 envelope glycoprotein of the hepatitis C virus that are critical for CD81 binding.. J. Virol.
80: 8695-8704
[Abstract]
[Full Text]
-
Helle, F., Wychowski, C., Vu-Dac, N., Gustafson, K. R., Voisset, C., Dubuisson, J.
(2006). Cyanovirin-N Inhibits Hepatitis C Virus Entry by Binding to Envelope Protein Glycans. J. Biol. Chem.
281: 25177-25183
[Abstract]
[Full Text]
-
Drummer, H. E., Boo, I., Maerz, A. L., Poumbourios, P.
(2006). A conserved gly436-trp-leu-ala-gly-leu-phe-tyr motif in hepatitis C virus glycoprotein e2 is a determinant of CD81 binding and viral entry.. J. Virol.
80: 7844-7853
[Abstract]
[Full Text]
-
Zhao, L.-J., Zhang, X.-L., Zhao, P., Cao, J., Cao, M.-M., Zhu, S.-Y., Liu, H.-Q., Qi, Z.-T.
(2006). Up-regulation of ERK and p38 MAPK signaling pathways by hepatitis C virus E2 envelope protein in human T lymphoma cell line. J. Leukoc. Biol.
80: 424-432
[Abstract]
[Full Text]
-
Bertaux, C., Dragic, T.
(2006). Different domains of CD81 mediate distinct stages of hepatitis C virus pseudoparticle entry.. J. Virol.
80: 4940-4948
[Abstract]
[Full Text]
-
Owsianka, A., Tarr, A. W., Juttla, V. S., Lavillette, D., Bartosch, B., Cosset, F.-L., Ball, J. K., Patel, A. H.
(2005). Monoclonal Antibody AP33 Defines a Broadly Neutralizing Epitope on the Hepatitis C Virus E2 Envelope Glycoprotein. J. Virol.
79: 11095-11104
[Abstract]
[Full Text]
-
Steinmann, D., Barth, H., Gissler, B., Schurmann, P., Adah, M. I., Gerlach, J. T., Pape, G. R., Depla, E., Jacobs, D., Maertens, G., Patel, A. H., Inchauspe, G., Liang, T. J., Blum, H. E., Baumert, T. F.
(2004). Inhibition of Hepatitis C Virus-Like Particle Binding to Target Cells by Antiviral Antibodies in Acute and Chronic Hepatitis C. J. Virol.
78: 9030-9040
[Abstract]
[Full Text]
-
McKeating, J. A., Zhang, L. Q., Logvinoff, C., Flint, M., Zhang, J., Yu, J., Butera, D., Ho, D. D., Dustin, L. B., Rice, C. M., Balfe, P.
(2004). Diverse Hepatitis C Virus Glycoproteins Mediate Viral Infection in a CD81-Dependent Manner. J. Virol.
78: 8496-8505
[Abstract]
[Full Text]
-
Op De Beeck, A., Voisset, C., Bartosch, B., Ciczora, Y., Cocquerel, L., Keck, Z., Foung, S., Cosset, F.-L., Dubuisson, J.
(2004). Characterization of Functional Hepatitis C Virus Envelope Glycoproteins. J. Virol.
78: 2994-3002
[Abstract]
[Full Text]
-
Bartosch, B., Vitelli, A., Granier, C., Goujon, C., Dubuisson, J., Pascale, S., Scarselli, E., Cortese, R., Nicosia, A., Cosset, F.-L.
(2003). Cell Entry of Hepatitis C Virus Requires a Set of Co-receptors That Include the CD81 Tetraspanin and the SR-B1 Scavenger Receptor. J. Biol. Chem.
278: 41624-41630
[Abstract]
[Full Text]
-
Cocquerel, L., Kuo, C.-C., Dubuisson, J., Levy, S.
(2003). CD81-Dependent Binding of Hepatitis C Virus E1E2 Heterodimers. J. Virol.
77: 10677-10683
[Abstract]
[Full Text]
-
Bartosch, B., Dubuisson, J., Cosset, F.-L.
(2003). Infectious Hepatitis C Virus Pseudo-particles Containing Functional E1-E2 Envelope Protein Complexes. JEM
197: 633-642
[Abstract]
[Full Text]
-
Lucas, M., Tsitoura, E., Montoya, M., Laliotou, B., Aslanoglou, E., Kouvatsis, V., Entwisle, C., Miller, J., Klenerman, P., Hadziyannis, A., Hadziyannis, S., Borrow, P., Mavromara, P.
(2003). Characterization of secreted and intracellular forms of a truncated hepatitis C virus E2 protein expressed by a recombinant herpes simplex virus. J. Gen. Virol.
84: 545-554
[Abstract]
[Full Text]
-
Kien, F., Abraham, J.-D., Schuster, C., Kieny, M. P.
(2003). Analysis of the subcellular localization of hepatitis C virus E2 glycoprotein in live cells using EGFP fusion proteins. J. Gen. Virol.
84: 561-566
[Abstract]
[Full Text]
-
Roccasecca, R., Ansuini, H., Vitelli, A., Meola, A., Scarselli, E., Acali, S., Pezzanera, M., Ercole, B. B., McKeating, J., Yagnik, A., Lahm, A., Tramontano, A., Cortese, R., Nicosia, A.
(2003). Binding of the Hepatitis C Virus E2 Glycoprotein to CD81 Is Strain Specific and Is Modulated by a Complex Interplay between Hypervariable Regions 1 and 2. J. Virol.
77: 1856-1867
[Abstract]
[Full Text]
-
Cocquerel, L., Quinn, E. R., Flint, M., Hadlock, K. G., Foung, S. K. H., Levy, S.
(2002). Recognition of Native Hepatitis C Virus E1E2 Heterodimers by a Human Monoclonal Antibody. J. Virol.
77: 1604-1609
[Abstract]
[Full Text]
-
Clayton, R. F., Owsianka, A., Aitken, J., Graham, S., Bhella, D., Patel, A. H.
(2002). Analysis of Antigenicity and Topology of E2 Glycoprotein Present on Recombinant Hepatitis C Virus-Like Particles. J. Virol.
76: 7672-7682
[Abstract]
[Full Text]
-
Lambot, M., Fretier, S., De Beeck, A. O., Quatannens, B., Lestavel, S., Clavey, V., Dubuisson, J.
(2002). Reconstitution of Hepatitis C Virus Envelope Glycoproteins into Liposomes as a Surrogate Model to Study Virus Attachment. J. Biol. Chem.
277: 20625-20630
[Abstract]
[Full Text]
-
Tsitoura, E., Lucas, M., Revol-Guyot, V., Epstein, A. L., Manservigi, R., Mavromara, P.
(2002). Expression of hepatitis C virus envelope glycoproteins by herpes simplex virus type 1-based amplicon vectors. J. Gen. Virol.
83: 561-566
[Abstract]
[Full Text]
-
Wellnitz, S., Klumpp, B., Barth, H., Ito, S., Depla, E., Dubuisson, J., Blum, H. E., Baumert, T. F.
(2002). Binding of Hepatitis C Virus-Like Particles Derived from Infectious Clone H77C to Defined Human Cell Lines. J. Virol.
76: 1181-1193
[Abstract]
[Full Text]
-
Quinn, E. R., Chan, C. H., Hadlock, K. G., Foung, S. K. H., Flint, M., Levy, S.
(2001). The B-cell receptor of a hepatitis C virus (HCV)-associated non-Hodgkin lymphoma binds the viral E2 envelope protein, implicating HCV in lymphomagenesis. Blood
98: 3745-3749
[Abstract]
[Full Text]
-
Hamaia, S., Li, C., Allain, J.-P.
(2001). The dynamics of hepatitis C virus binding to platelets and 2 mononuclear cell lines. Blood
98: 2293-2300
[Abstract]
[Full Text]
-
Owsianka, A., Clayton, R. F., Loomis-Price, L. D., McKeating, J. A., Patel, A. H.
(2001). Functional analysis of hepatitis C virus E2 glycoproteins and virus-like particles reveals structural dissimilarities between different forms of E2. J. Gen. Virol.
82: 1877-1883
[Abstract]
[Full Text]
-
Patel, A. H., Wood, J., Penin, F., Dubuisson, J., McKeating, J. A.
(2000). Construction and characterization of chimeric hepatitis C virus E2 glycoproteins: analysis of regions critical for glycoprotein aggregation and CD81 binding. J. Gen. Virol.
81: 2873-2883
[Abstract]
[Full Text]
-
Allander, T., Drakenberg, K., Beyene, A., Rosa, D., Abrignani, S., Houghton, M., Widell, A., Grillner, L., Persson, M. A. A.
(2000). Recombinant human monoclonal antibodies against different conformational epitopes of the E2 envelope glycoprotein of hepatitis C virus that inhibit its interaction with CD81. J. Gen. Virol.
81: 2451-2459
[Abstract]
[Full Text]
-
Heile, J. M., Fong, Y.-L., Rosa, D., Berger, K., Saletti, G., Campagnoli, S., Bensi, G., Capo, S., Coates, S., Crawford, K., Dong, C., Wininger, M., Baker, G., Cousens, L., Chien, D., Ng, P., Archangel, P., Grandi, G., Houghton, M., Abrignani, S.
(2000). Evaluation of Hepatitis C Virus Glycoprotein E2 for Vaccine Design: an Endoplasmic Reticulum-Retained Recombinant Protein Is Superior to Secreted Recombinant Protein and DNA-Based Vaccine Candidates. J. Virol.
74: 6885-6892
[Abstract]
[Full Text]